Johnson & Johnson (JNJ) Pays $181 Million to States for Risperdal Marketing
8/31/2012 6:35:06 AM
Thirty-six states and the District of Columbia will share in $181 million that Johnson & Johnson has agreed to pay to resolve allegations of inappropriate marketing of the antipsychotic drug Risperdal. Pennsylvania, New Jersey, and Delaware are among the states that filed similar complaints in their own courts Thursday and will get $8.4 million, $5.3 million, and $4.2 million, respectively. New York will get $9 million. Johnson & Johnson has headquarters in New Brunswick, N.J.; its Janssen Pharmaceuticals subsidiary, which makes Risperdal, is based in Titusville.